This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
Researchers may develop nanodrugs due to their smaller surface area to allows drugs to dissolve faster, or nanoparticles may encapsulate drugs, so they last longer in the body. Since then, the drug has been used off-label in breast cancer and other types of cancer. He says, “It gave a new lease [on] life to the field”.
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdeliverysystems and medical devices.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. Consequently, pharmaceutical and biotech companies are increasingly looking to provide devices that allow patients to self-administer drugs. It just felt right.
Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. The engineered cells reduced inflammation and prevented a type of damage to bone, known as bone erosion, in a mouse model of rheumatoid arthritis. million adults in the United States.
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Our Social Media Platform.
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise.
As part of SMi’s leading injectable series, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design, advances in parenteral device platforms and development, insights into growing integration of digital health and deep dives into recent case studies on novel deliverysystems.
It is worth mentioning that the first radiopharmaceutical peptide-drug conjugate Luthathera was approved by United States Food and Drug Administration (USFDA) in 2018 for the treatment of gastroenteropancreatic neuroendocrine tumors. It consists of somatostatin-derived peptide and DOTA complexed with radioactive isotope 77 Lu.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content